BUSINESS
Medical devices maker Polymed eyes global expansion with new plants, strategic M&A
Polymed has set an ambitious target to grow its US revenue to ;$20-25 million opportunity' within the next three to four years, driven by new contracts and FDA approvals.
BUSINESS
Kilitch Drugs eyes Rs 1,000 crore revenue with Khopoli expansion regulated market entry
Mehta said that the Khopoli plant will enable exports to regulated markets starting FY28–29, bringing previously outsourced products in-house saving costs, and expanding the product portfolio, which will include injectables, eye drops, and chronic therapies.
BUSINESS
Delhi High Court asks drug regulator to look into concerns over approval for weight-loss drugs
A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, potentially overlooking regional health profiles and genetic factors
BUSINESS
Sigachi blast exposes recurring safety failures and worker deaths in Indian factories
While the investigation into the June 30 blast is underway, the company said on Wednesday that it was not a reactor explosion.
BUSINESS
Superhealth in talks to raise Rs 100 crore to setup hospital chain
The first Superhealth hospital is set to launch in July in Koramangala, Bangalore. The facility's core unique selling propositions include zero wait times for patients and zero commissions for doctors.
BUSINESS
Torrent Pharma expects to recover JB Pharma acquisition cost in 2.5 years from taking control
Torrent expects to reach a peak leverage of 2.8x by FY27 in a worst-case scenario, but anticipates reducing it to below 0.5x within two years post-merger.
BUSINESS
Biological E partners with China’s Recbio to manufacture HPV9 vaccine for India, global markets
Under the terms of the deal, Recbio will transfer the technology and supply the drug substance (DS) to BE, enabling the Indian firm to formulate, fill, and package the vaccine.
BUSINESS
Torrent Pharma to become India’s fifth-largest drugmaker after JB Pharma acquisition
The acquisition and subsequent merger will create a pharmaceutical powerhouse with combined revenues exceeding Rs 15,000 crore and EBITDA of over Rs 4,800 crore, based on FY25 pro forma figures.
BUSINESS
Torrent Pharma revives talks to acquire KKR’s stake in JB Pharma; deal expected soon
KKR’s stake is worth approximately Rs 13,400 crore considering the J B Pharma stock’s closing price of Rs 1,802.9 per share on June 27.
BUSINESS
Vertex Pharma's stem cell therapy may have potential to cure type-1 diabetes, shows clinical trial
During a clinical trial, around 83% (10 out of 12) of patients who received a full dose of Zimislecel achieved complete insulin independence within one year of treatment.
BUSINESS
AstraZeneca pumps in Rs 166 crore into Global Hub in Bengaluru, will add 400 new jobs
The new facility will house nearly 1300 employees, including 400 new jobs, supporting the company's capabilities in AI-powered innovation across Research and Development, Global Business Services, IT, and Digital Health operations.
BUSINESS
French drugmaker Servier targets India expansion with cancer therapies, R&D
The company is also looking to broaden generics portfolio, explore clinical trials and examine the possibility of a global capability centre, Servier India MD Aurélien Breton tells Moneycontrol
BUSINESS
CDSCO allows Lilly to launch weight-loss drug Mounjaro in pen format
The KwikPen is a multi-dose, single-patient-use prefilled pen designed for once-in-a week administration
BUSINESS
Bharat Biotech, GSK to halve malaria vaccine price to less than $5 per dose
Bharat Biotech has entered into partnership in 2021 to produce part of the malaria vaccine that has been developed by British drugmaker GSK, the company has invested $200 million in building manufacturing capacities for the vaccine.
BUSINESS
Air India employees looking at leadership to guide them at a time of despair
Multiple pilots and cabin crew Moneycontrol spoke to also indicated that while there is a heightened sense of compassion and concern being expressed by senior leaders with regard to the work load and mental well-being of employees following the June 12 crash, many have questioned the sincerity, delayed recognition and extent of the compassion being displayed by senior leadership.
BUSINESS
Novo Nordisk follows smart pricing for Wegovy in India; easy to use, says top local executive
'We wanted to price it in India in a way which is comparable to the therapies that are available,' said Vikrant Shrotriya, Managing Director of Novo Nordisk India, in an interview with Moneycontrol.
TRENDS
Novo Nordisk launches blockbuster weight loss drug Wegovy in India
The drug will follow a four-week cycle for dosage, starting with the smallest dose of 0.25 mg per week for four weeks, followed by a gradual increase in dosage.
BUSINESS
Indira IVF acquires Ahmedabad-based Banker IVF to expand fertility care services
The collaboration will increase Indira IVF's presence in Gujarat, adding to its existing centers in Ahmedabad, Vadodara, Rajkot, Mehsana, and other key locations, the company said.
BUSINESS
Biocon’s Rs 4,500 crore QIP to help retire debt, fuel new launches, says CEO Sidharth Mittal
Biocon’s debt profile has been under investor scrutiny after a strategic acquisition of Viatris Inc's biosimilars business for roughly $3.3 billion in 2022. This deal, while transformative for Biocon Biologics, had significantly increased the company's leverage.
BUSINESS
What does Gilead’s twice-a-year shot means for fight against HIV? When will India get Yeztugo?
The US FDA on June 18 gave its nod to Yeztugo, which can prove to be turning point in the battle against HIV but its high price and access remains a concern
BUSINESS
How a Mumbai startup stepped up during Covid to disrupt the global biopharma supply chain
Founded in 2017 by industry veterans Ankush Kapoor and Sachin Joshi, PharmNXT pivoted from being a distributor of European bioprocessing technologies to becoming a full-fledged manufacturer—building India’s first domestic supply chain for single-use biopharma systems.
BUSINESS
Abbott to distribute MSD's diabetes drug and its combinations in India
The drug patents expired in India in July 2022, which has triggered a wave of generic launches and steep price corrections across the market.
BUSINESS
Indian pharma companies sit on record cash pile, set sights on acquisitions
In FY25 alone, the cash pile increased by over Rs 10,200 crore, underscoring a decisive shift in the capital allocation priorities of India’s drugmakers
BUSINESS
Quadria Group launches $300 million HealthQuad Fund III to build India’s largest healthcare investment platform
HealthQuad Fund III will focus on early to late-stage investments across India’s healthcare value chain, targeting tech-enabled models in diagnostics, chronic care, and digital health.
